In summary, the three proteins mentioned above are most likely the important targets of the four active ingredients we screened; therefore, we speculate that these four active ingredients may have expected therapeutic effects on NSCLC and breast cancer by inhibiting the EGFR and MET (49, 50) in the following text. The gene discussed is MET; the disease is breast carcinoma.